Pink SheetEisai and Eli Lilly are to appeal against today’s final decision by England’s health technology assessment institute, NICE, to deny funding for their respective Alzheimer’s disease drugs – Leqembi and
ScripThe biggest upcoming catalysts for NewAmsterdam Pharma’s CETP inhibitor obicetrapib as a means for lowering low-density lipoprotein cholesterol (LDL-C) are regulatory submissions later this year based
ScripAlzheimer’s disease (AD) drug development during the last several years showed that amyloid-clearing medicines worked best in patients treated early in their disease progression, and the first two ant